Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Clinical trial NCT04272125 · UNKNOWN
Trial details
- NCT number
- NCT04272125
- Sponsor
- Chongqing Precision Biotech Co., Ltd
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-01
- Primary completion
- 2023-12-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.